NCT05914077招募中3 期
Aspiration of Duodenopancreatic Juice After Secretin Stimulation (ADPJ-secr-) vs Endoscopic Aspiration (EUS-FNA) for Molecular Analysis of Intraductal Papillary Mucinous Intraductal Neoplasia (IPMN).
Fundacion Clinic per a la Recerca Biomédica1 个研究点 分布在 1 个国家目标入组 140 人开始时间: 2023年9月13日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 发起方
- 入组人数
- 140
- 试验地点
- 1
- 主要终点
- Proportion of patients with IPMN with GNAS and KRAS mutations in intracystic fluid obtained by EUS-FNA versus pancreatic juice obtained by ADPJ-secr after both techniques.
研究概览
简要总结
Study to evaluate aspiration of duodenopancreatic juice after secretin stimulation (ADPJ-secr)versus endoscopic ultrasound-guided fine needle aspiration (EUS-FNA) for molecular analysis of intraductal papillary mucinous intraductal neoplasia.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Diagnostic
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Be a man or woman over 18 years of age.
- •Willing to comply with the study procedures described in the protocol.
- •Willing and able to give written informed consent.
- •Meet at least one of the following three criteria in relation to the diagnosis or prognosis of IPMN:
- •4.1 Diagnosis of IMPN based on evidence of major criteria or existence of at least 2 minor criteria. Major criterion: Typical findings on MRI and/or EUS (single or multiple cysts with clear ductal communication and/or focal or diffuse dilatation # 5 mm in diameter of the main pancreatic duct without apparent obstructive cause). Minor criteria: a) Mucosecretory cells and/or extracellular mucin on cytological examination of intracystic fluid. b) Clear mucoid or filmy appearance of the intracystic fluid. c) Intracystic fluid CEA concentration >192 ng/mL or intracystic glucose < 50 mg/dL.
- •4.2 IPMN with cysts with a diameter # 10 mm and/or focal or diffuse dilatation of the main pancreatic duct with a diameter # 7 mm requiring EUS-FNA for diagnostic purposes or to assess risk or existence of malignancy following the main clinical practice guidelines.
- •4.3 IPMN with indication for surgical resection of the lesion.
- •In case of a woman of childbearing age*, willing to use highly effective contraception or practice sexual abstinence from the screening visit until one week after undergoing the procedure under study. Highly effective contraceptive methods will include: combined oral, intravaginal or transdermal hormonal contraceptives (containing oestrogens and progestogens) associated with ovulation inhibition; oral, injectable or implantable progestogen-only hormonal contraception associated with ovulation inhibition; intrauterine device; intrauterine hormone-releasing system; bilateral tubal occlusion; vasectomised partner; and sexual abstinence.
- •If you are a woman of childbearing age, be willing to undergo a urine pregnancy test prior to inclusion in the study.
排除标准
- •History of surgery that prevents endoscopic access to the major duodenal papilla in the case of ADPJ-secr, or to the area of the stomach or intestine from which to perform FNA.
- •History of acute pancreatitis during the 30 days prior to inclusion.
- •Pregnant women, women who may become pregnant during the month prior to inclusion or women who are breastfeeding.
- •Coagulopathy (PT < 25%, INR > 1.5, platelets < 50,000/mL) preventing FNA.
- •Renal failure with GFR < 30 mL/min or patients on dialysis.
- •Known hypersensitivity to any component of the ChiRhoStim® (human secretin) formulation.
- •Any clinically relevant medical condition that, in the opinion of the investigator, makes the patient unfit to participate in the study (underlying haematological disorders, autoimmune disease, immunodeficiency, gastrointestinal, psychiatric, renal, hepatic and cardiopulmonary disorders).
研究组 & 干预措施
Duodenopancreatic aspiration after secretin stimulation + EUS-FNA
Experimental
Duodenopancreatic aspiration after secretin stimulation will be performed followed by endoscopic ultrasound-guided fine needle aspiration (EUS-FNA)
干预措施: Secretin (Drug)
Duodenopancreatic aspiration after secretin stimulation + EUS-FNA
Experimental
Duodenopancreatic aspiration after secretin stimulation will be performed followed by endoscopic ultrasound-guided fine needle aspiration (EUS-FNA)
干预措施: Endoscopic aspiration (Procedure)
Duodenopancreatic aspiration after secretin stimulation + EUS-FNA
Experimental
Duodenopancreatic aspiration after secretin stimulation will be performed followed by endoscopic ultrasound-guided fine needle aspiration (EUS-FNA)
干预措施: Endoscopic ultrasound-guided fine needle aspiration (Procedure)
EUS-FNA + duodenopancreatic aspiration after secretin stimulation
Experimental
Endoscopic ultrasound-guided fine needle aspiration (EUS-FNA) will be performed followed by duodenopancreatic aspiration after secretin stimulation
干预措施: Secretin (Drug)
EUS-FNA + duodenopancreatic aspiration after secretin stimulation
Experimental
Endoscopic ultrasound-guided fine needle aspiration (EUS-FNA) will be performed followed by duodenopancreatic aspiration after secretin stimulation
干预措施: Endoscopic aspiration (Procedure)
EUS-FNA + duodenopancreatic aspiration after secretin stimulation
Experimental
Endoscopic ultrasound-guided fine needle aspiration (EUS-FNA) will be performed followed by duodenopancreatic aspiration after secretin stimulation
干预措施: Endoscopic ultrasound-guided fine needle aspiration (Procedure)
结局指标
主要结局
Proportion of patients with IPMN with GNAS and KRAS mutations in intracystic fluid obtained by EUS-FNA versus pancreatic juice obtained by ADPJ-secr after both techniques.
时间窗: Through study completion, an average of 30 months
In intracystic fluid obtained by EUS-FNA versus pancreatic juice obtained by ADPJ-secr after both techniques.
次要结局
- Proportion of patients undergoing pancreatic resection with Tp53 mutations(Through study completion, an average of 30 months)
- Proportion of suitable samples obtained by the two techniques under study (ADPJ-secr and EUS-FNA) for molecular analysis.(Through study completion, an average of 30 months)
- Proportion of patients undergoing pancreatic resection without a pathological diagnosis of IPMN who do not have GNAS and/or KRAS mutations(Through study completion, an average of 30 months)
- DNA concentration expressed in ng/µl(Through study completion, an average of 30 months)
- Proportion of patients undergoing pancreatic resection with a pathological diagnosis of IPMN who have mutations in GNAS and/or KRAS(Through study completion, an average of 30 months)
- To evaluate association between mutational status in the samples obtained by both techniques in relation to morphological characteristics of the lesion (diameter of the largest cystic lesion) obtained by EUS.(Through study completion, an average of 30 months)
- To evaluate association between mutational status (mutated GNAS/KRAS versus non-mutated GNAS/KRAS [wild type]) in the samples obtained by both techniques under study (ADPJ-secr and EUS-FNA) in relation to chronic liver disease.(Through study completion, an average of 30 months)
- Proportion of patients with IPMN with Tp53 mutations.(Through study completion, an average of 30 months)
- To evaluate association between mutational status (mutated GNAS/KRAS versus non-mutated GNAS/KRAS [wild type]) in the samples obtained by both techniques under study (ADPJ-secr and EUS-FNA) in relation to chronic kidney disease.(Through study completion, an average of 30 months)
- To evaluate association between mutational status (mutated GNAS/KRAS versus non-mutated GNAS/KRAS [wild type]) in the samples obtained by both techniques under study (ADPJ-secr and EUS-FNA) in relation to blood levels of platelets (U/L)(Through study completion, an average of 30 months)
- To evaluate association between mutational status (mutated GNAS/KRAS versus non-mutated GNAS/KRAS [wild type]) in the samples obtained by both techniques under study (ADPJ-secr and EUS-FNA) in relation to blood levels of CA 19.9 (u/L)(Through study completion, an average of 30 months)
- Proportion of patients undergoing pancreatic resection without Tp53 mutations.(Through study completion, an average of 30 months)
- To evaluate association between mutational status in the samples obtained by both techniques in relation to morphological characteristics of the lesion (mural nodules) obtained by EUS.(Through study completion, an average of 30 months)
- To evaluate association between mutational status in the samples obtained by both techniques in relation to morphological characteristics of the lesion (intraductal calcifications) obtained by EUS.(Through study completion, an average of 30 months)
- To evaluate association between mutational status (mutated GNAS/KRAS versus non-mutated GNAS/KRAS [wild type]) in the samples obtained by both techniques under study (ADPJ-secr and EUS-FNA) in relation to age(Through study completion, an average of 30 months)
- To evaluate association between mutational status (mutated GNAS/KRAS versus non-mutated GNAS/KRAS [wild type]) in the samples obtained by both techniques under study (ADPJ-secr and EUS-FNA) in relation to sex(Through study completion, an average of 30 months)
- To evaluate association between mutational status (mutated GNAS/KRAS versus non-mutated GNAS/KRAS [wild type]) in the samples obtained by both techniques under study (ADPJ-secr and EUS-FNA) in relation to neoplasms.(Through study completion, an average of 30 months)
- To evaluate association between mutational status (mutated GNAS/KRAS versus non-mutated GNAS/KRAS [wild type]) in the samples obtained by both techniques under study (ADPJ-secr and EUS-FNA) in relation to history of acute pancreatitis(Through study completion, an average of 30 months)
- To evaluate association between mutational status (mutated GNAS/KRAS versus non-mutated GNAS/KRAS [wild type]) in the samples obtained by both techniques under study (ADPJ-secr and EUS-FNA) in relation to time since diagnosis of IPMN(Through study completion, an average of 30 months)
- To evaluate association between mutational status (mutated GNAS/KRAS versus non-mutated GNAS/KRAS [wild type]) in the samples obtained by both techniques under study (ADPJ-secr and EUS-FNA) in relation to blood levels of total bilirrubin(Through study completion, an average of 30 months)
- To evaluate association between mutational status in the samples obtained by both techniques in relation to morphological characteristics of the lesion (maximum diameter of the main pancreatic duct) obtained by EUS.(Through study completion, an average of 30 months)
- To evaluate association between mutational status in the samples obtained by both techniques in relation to morphological characteristics of the lesion (type of main pancreatic duct dilatation) obtained by EUS.(Through study completion, an average of 30 months)
- To evaluate association between mutational status in the samples obtained by both techniques in relation to morphological characteristics of the lesion (presence > 1 cystic lesion) obtained by EUS.(Through study completion, an average of 30 months)
- To evaluate association between mutational status in the samples obtained by both techniques in relation to morphological characteristics of the lesion (signs of chronic pancreatitis) obtained by EUS.(Through study completion, an average of 30 months)
- To evaluate association between mutational status (mutated GNAS/KRAS versus non-mutated GNAS/KRAS [wild type]) in the samples obtained by both techniques under study (ADPJ-secr and EUS-FNA) in relation to smoking(Through study completion, an average of 30 months)
- To evaluate association between mutational status (mutated GNAS/KRAS versus non-mutated GNAS/KRAS [wild type]) in the samples obtained by both techniques under study (ADPJ-secr and EUS-FNA) in relation to chronic alcohol consumption(Through study completion, an average of 30 months)
- To evaluate association between mutational status (mutated GNAS/KRAS versus non-mutated GNAS/KRAS [wild type]) in the samples obtained by both techniques under study (ADPJ-secr and EUS-FNA) in relation to heart failure(Through study completion, an average of 30 months)
- To evaluate association between mutational status (mutated GNAS/KRAS versus non-mutated GNAS/KRAS [wild type]) in the samples obtained by both techniques under study (ADPJ-secr and EUS-FNA) in relation to blood levels of amylase(Through study completion, an average of 30 months)
- To evaluate association between mutational status (mutated GNAS/KRAS versus non-mutated GNAS/KRAS [wild type]) in the samples obtained by both techniques under study (ADPJ-secr and EUS-FNA) in relation to blood levels of lipase(Through study completion, an average of 30 months)
- To evaluate association between mutational status (mutated GNAS/KRAS versus non-mutated GNAS/KRAS [wild type]) in the samples obtained by both techniques under study (ADPJ-secr and EUS-FNA) in relation to blood levels of GGT (U/L)(Through study completion, an average of 30 months)
- To evaluate association between mutational status (mutated GNAS/KRAS versus non-mutated GNAS/KRAS [wild type]) in the samples obtained by both techniques under study (ADPJ-secr and EUS-FNA) in relation to blood levels of glycated hemoglobin.(%).(Through study completion, an average of 30 months)
- Proportion of patients with Serious Adverse Events(At 24 hours and 7 days after the techniques under study.)
- To evaluate association between mutational status in the samples obtained by both techniques in relation to morphological characteristics of the lesion (location of the lesion) obtained by EUS.(Through study completion, an average of 30 months)
- To evaluate association between mutational status in the samples obtained by both techniques in relation to morphological characteristics of the lesion (pancreatic atrophy) obtained by EUS.(Through study completion, an average of 30 months)
- To evaluate association between mutational status (mutated GNAS/KRAS versus non-mutated GNAS/KRAS [wild type]) in the samples obtained by both techniques under study (ADPJ-secr and EUS-FNA) in relation to hypertension(Through study completion, an average of 30 months)
- To evaluate association between mutational status (mutated GNAS/KRAS versus non-mutated GNAS/KRAS [wild type]) in the samples obtained by both techniques under study (ADPJ-secr and EUS-FNA) in relation to type 2 diabetes mellitus(Through study completion, an average of 30 months)
- To evaluate association between mutational status (mutated GNAS/KRAS versus non-mutated GNAS/KRAS [wild type]) in the samples obtained by both techniques under study (ADPJ-secr and EUS-FNA) in relation to previous diagnosis of chronic pancreatitis(Through study completion, an average of 30 months)
- To evaluate association between mutational status (mutated GNAS/KRAS versus non-mutated GNAS/KRAS [wild type]) in the samples obtained by both techniques under study (ADPJ-secr and EUS-FNA) in relation to morphological type of IPMN(Through study completion, an average of 30 months)
- To evaluate association between mutational status (mutated GNAS/KRAS versus non-mutated GNAS/KRAS [wild type]) in the samples obtained by both techniques under study (ADPJ-secr and EUS-FNA) in relation to family history (1st degree) of pancreatic cancer(Through study completion, an average of 30 months)
- To evaluate association between mutational status (mutated GNAS/KRAS versus non-mutated GNAS/KRAS [wild type]) in the samples obtained by both techniques under study (ADPJ-secr and EUS-FNA) in relation to blood levels of creatinine(Through study completion, an average of 30 months)
- To evaluate association between mutational status (mutated GNAS/KRAS versus non-mutated GNAS/KRAS [wild type]) in the samples obtained by both techniques under study (ADPJ-secr and EUS-FNA) in relation to blood levels of ALT (U/L)(Through study completion, an average of 30 months)
- To evaluate association between mutational status (mutated GNAS/KRAS versus non-mutated GNAS/KRAS [wild type]) in the samples obtained by both techniques under study (ADPJ-secr and EUS-FNA) in relation to blood levels of AST(Through study completion, an average of 30 months)
- To evaluate association between mutational status (mutated GNAS/KRAS versus non-mutated GNAS/KRAS [wild type]) in the samples obtained by both techniques under study (ADPJ-secr and EUS-FNA) in relation to blood levels of alkaline phosphatase (U/L)(Through study completion, an average of 30 months)
- To evaluate association between mutational status (mutated GNAS/KRAS versus non-mutated GNAS/KRAS [wild type]) in the samples obtained by both techniques under study (ADPJ-secr and EUS-FNA) in relation to blood levels of hemoglobin (g/L)(Through study completion, an average of 30 months)
- To evaluate association between mutational status (mutated GNAS/KRAS versus non-mutated GNAS/KRAS [wild type]) in the samples obtained by both techniques under study (ADPJ-secr and EUS-FNA) in relation to blood levels of CEA (U/l)(Through study completion, an average of 30 months)
- To assess whether mutational status predicts the occurrence of adverse effects associated with the techniques under study at 24 hours and 7 days following the performance of the techniques under study.(Through study completion, an average of 30 months)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
不适用
Pancreatic Juice Diagnosis From DuodenumPancreatic AdenocarcinomaNCT01699698Olympus Corporation105
招募中
不适用
Analysis of the secretin stimulation for pancreatic juice cytologyPancreatic diseasesJPRN-UMIN000018557Department of Surgery and Oncology, Graduate School of Medical Sciences, Kyushu University250
招募中
不适用
Vinegar-induced Collection of Duodenal Pancreatic Juice Via Endoscopic UltrasoundPancreatic CancerNCT05617872Peking Union Medical College Hospital75
已完成
不适用
Intraductal Secretin Stimulation Test: What Is the Proper Collection Time?Cholangiopancreatography, Endoscopic RetrogradeNCT03263481Indiana University8
尚未招募
Unknown
Research on ingenious serial pancreatic juice aspiration cytological examination for abnormal pancreatic duct morphology and genetic analysis using pancreatic juiceearly-stage pancreatic cancerJPRN-UMIN000050540agoya University Hospital50